Your doctor may prescribe Azulfidine EN to treat a variety of different autoimmune conditions. It is commonly prescribed forrheumatoid arthritis (RA), ulcerative colitis (UC), ankylosing spondylitis (off-label), Crohn’s disease (off-label), and psoriatic arthritis. Azulfidine works by suppressing overacting cells of the immune system that are causing inflammation. Fact Table Formula C18H14N4O5S License US FDA Bioavailability Less than 15% Legal status Rx-only Chemical Name Sulfasalazine Elimination half-life 5-10 hours Dosage (Strength) 500mg Pregnancy Safe Brands Azulfidine Protein binding More than 99.3% PubChem CID 5339 MedlinePlus a682204 ChEBI 9334 ATC code A07EC01 DrugBank DB00795 KEGG D00448 Routes of administration By mouth
Azulfidine EN (Sulfasalazine) Delayed Release
- Azulfidine can be taken with or without food. The tablets have an enteric coating, so they cannot be chewed, crushed, or split. They should be swallowed whole. The enteric coating ensures that the active ingredient is not broken down by stomach acid and reaches the area where it is needed in the intestines. Rheumatoid arthritis (RA): Starting dose is 500 once or twice a day. The dose may be increased to 1000 mg twice daily for 12 weeks., Ulcerative colitis (UC): Starting dose is 3000-4000 mg per day until in remission, and then 2000 mg per day., Ankylosing spondylitis (off-label): 500-3000 mg per day in divided doses., Crohn's disease (off-label): 3000-6000 mg per day in divided doses for up to 16 weeks., Psoriatic arthritis (off-label): 500-3000 mg per day in divided doses.
